Literature DB >> 1373205

Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.

J F Dedieu1, J Ronco, S van der Werf, J M Hogle, Y Henin, M Girard.   

Abstract

Sequences from the principal neutralization domain of human immunodeficiency virus type 1 (HIV-1) strain LAI or RF have been expressed in antigenic site 1 of the capsid of the Sabin strain of poliovirus type 1. A number of the resulting chimeras were viable. Viable variants bearing mutations within the insertion site spontaneously arose from several nonviable chimeras. In general, these mutations result in a decrease in positive charge in the substituted antigenic site 1. Two of the chimeras were genetically stable and have been further characterized. Both chimeras were neutralized by various HIV-1 neutralizing antibodies. In rabbits, both chimeras produced high levels of antibodies which react with HIV-1 gp120/160 in immunoprecipitation and enzyme-linked immunosorbent assays. One of the chimeras (HIV-1LAI) produced a significant but weak HIV-1 neutralizing response.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1373205      PMCID： PMC241080     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  47 in total

1.  The effect of site and mode of expression of a heterologous antigenic determinant on the properties of poliovirus hybrids.

Authors:  A D Murdin; C Mirzayan; A Kameda; E Wimmer
Journal:  Microb Pathog       Date:  1991-01       Impact factor: 3.738

2.  Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity.

Authors:  R H Meloen; R M Liskamp; J Goudsmit
Journal:  J Gen Virol       Date:  1989-06       Impact factor: 3.891

3.  Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles.

Authors:  M L Michel; M Mancini; E Sobczak; V Favier; D Guetard; E M Bahraoui; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

4.  Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys.

Authors:  P Putkonen; R Thorstensson; L Ghavamzadeh; J Albert; K Hild; G Biberfeld; E Norrby
Journal:  Nature       Date:  1991-08-01       Impact factor: 49.962

5.  Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers.

Authors:  P Rossi; V Moschese; P A Broliden; C Fundaró; I Quinti; A Plebani; C Giaquinto; P A Tovo; K Ljunggren; J Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

6.  Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.

Authors:  G Zwart; H Langedijk; L van der Hoek; J J de Jong; T F Wolfs; C Ramautarsing; M Bakker; A de Ronde; J Goudsmit
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

7.  An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16.

Authors:  O Jenkins; J Cason; K L Burke; D Lunney; A Gillen; D Patel; D J McCance; J W Almond
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.

Authors:  K Javaherian; A J Langlois; G J LaRosa; A T Profy; D P Bolognesi; W C Herlihy; S D Putney; T J Matthews
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

9.  Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant.

Authors:  J C Griffiths; E L Berrie; L N Holdsworth; J P Moore; S J Harris; J M Senior; S M Kingsman; A J Kingsman; S E Adams
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205
View more
  17 in total

1.  Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice.

Authors:  N M Chapman; K S Kim; S Tracy; J Jackson; K Höfling; J S Leser; J Malone; P Kolbeck
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Vaccination with an adenoviral vector that encodes and displays a retroviral antigen induces improved neutralizing antibody and CD4+ T-cell responses and confers enhanced protection.

Authors:  Wibke Bayer; Matthias Tenbusch; Ruth Lietz; Lena Johrden; Simone Schimmer; Klaus Uberla; Ulf Dittmer; Oliver Wildner
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

3.  Immunization against rabies with plant-derived antigen.

Authors:  A Modelska; B Dietzschold; N Sleysh; Z F Fu; K Steplewski; D C Hooper; H Koprowski; V Yusibov
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 4.  Emergency Services of Viral RNAs: Repair and Remodeling.

Authors:  Vadim I Agol; Anatoly P Gmyl
Journal:  Microbiol Mol Biol Rev       Date:  2018-03-14       Impact factor: 11.056

5.  Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences.

Authors:  A D Smith; D A Resnick; A Zhang; S C Geisler; E Arnold; G F Arnold
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

6.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Authors:  J C Griffiths; S J Harris; G T Layton; E L Berrie; T J French; N R Burns; S E Adams; A J Kingsman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  Attenuated Mengo virus: a new vector for live recombinant vaccines.

Authors:  R Altmeyer; M Girard; S van der Werf; V Mimic; L Seigneur; M F Saron
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

8.  Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1.

Authors:  S Li; V Polonis; H Isobe; H Zaghouani; R Guinea; T Moran; C Bona; P Palese
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

Review 9.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

10.  A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.

Authors:  M Tardy-Panit; B Blondel; A Martin; F Tekaia; F Horaud; F Delpeyroux
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.